Form 4: Merit Medical Systems Director Sells Over 3,500 Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
A director at Merit Medical Systems, David Floyd, sold 3,515 shares of common stock for approximately $94.16 per share, as part of a pre-established Rule 10b5-1 trading plan.
Summary
- David Floyd, a Director of Merit Medical Systems Inc. (MMSI), reported a sale of common stock on May 30, 2025.
- Mr. Floyd disposed of 3,515 shares of MMSI common stock at a weighted average price of $94.16 per share, with individual transaction prices ranging from $93.87 to $94.46.
- The total value of the shares sold amounts to approximately $330,990.40.
- This transaction was executed under a Rule 10b5-1 trading plan adopted by Mr. Floyd on February 28, 2025.
- Following the sale, Mr. Floyd directly owns 8,602 shares of common stock.
- Additionally, Mr. Floyd indirectly beneficially owns 1,584 shares through the David & Lisa Floyd Family LP and 4,880 shares through the David K. Floyd Living Trust.
Sentiment
Score: 5
Explanation: Neutral. A Form 4 reports an insider transaction. While selling can sometimes be seen negatively, the presence of a 10b5-1 plan indicates a pre-scheduled sale, which is generally viewed as less opportunistic and more neutral.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, which indicates a pre-scheduled transaction and can mitigate concerns about opportunistic insider trading, enhancing transparency and compliance.
Negatives
- Insider selling, even if pre-planned, can sometimes be misinterpreted by the market as a signal of reduced confidence, although this is less common with 10b5-1 plans.
- The transaction reduces the director's direct ownership stake in the company.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | Director David Floyd adopted a Rule 10b5-1 trading plan on February 28, 2025, to pre-arrange stock sales. | 02/28/2025 | This practice enhances transparency and mitigates concerns about insider trading by scheduling sales in advance, aligning with corporate governance best practices. |
Stakeholder Impact
- Shareholders may note the insider sale, but the context of a Rule 10b5-1 plan typically lessens any negative interpretation, as it suggests a pre-planned financial management decision rather than a reaction to new material information.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date Rule 10b5-1 trading plan was adopted by David Floyd. |
| 05/30/2025 | Date of transaction (sale of common stock by David Floyd). |
| 06/03/2025 | Date Form 4 was signed by Attorney-in-Fact. |
Keywords
Merit Medical Systems, MMSI, SEC Form 4, Insider Trading, Stock Sale, David Floyd, Director, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.